Fluoxetin ( DrugBank: Fluoxetin )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎6
179ウィリアムズ症候群1
206脆弱X症候群1

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01910259
(ClinicalTrials.gov)
December 18, 201419/7/2013MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation TrialA Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.Secondary Progressive Multiple SclerosisDrug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: PlaceboUniversity College, LondonMedical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of WarwickCompleted25 Years65 YearsAll445Phase 2United Kingdom
2EUCTR2012-005394-31-GB
(EUCTR)
01/04/201405/09/2014MS-SMART: A Trial of Efficacy (usefulness) of 3 Neuroprotective Drugs in SPMSMS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis - MS-SMART: Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial Mutliple Sclerosis (Secondary Progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Rilutek
Product Name: Rilutek
INN or Proposed INN: Riluzole
Trade Name: Amiloride
Product Name: Amiloride
INN or Proposed INN: Amiloride
Trade Name: Fluoxetine
Product Name: Fluoxetine
INN or Proposed INN: Fluoxetine hydrochloride
UCLNULLNot Recruiting Female: yes
Male: yes
440 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
3EUCTR2011-003775-11-BE
(EUCTR)
12/01/201207/09/2011Fluoxetine therapy for multiple sclerosisFluoxetine therapy for multiple sclerosis - FLUOX-PMS progressive multiple sclerosis
MedDRA version: 16.0;Level: PT;Classification code 10063401;Term: Primary progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 16.0;Classification code 10063400;Term: Secondary progressive multiple sclerosis;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Fluoxetine
Product Name: Fluoxetine
Product Code: fluoxetine
INN or Proposed INN: Fluoxetine
Other descriptive name: N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Belgium
4NCT01436643
(ClinicalTrials.gov)
November 201116/9/2011Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With DepressionA 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate DepressionDepression;Relapsing-remitting Multiple SclerosisDrug: Venlafaxine;Drug: Fluoxetine;Drug: Citalopram;Drug: FingolimodNovartis PharmaceuticalsNULLTerminated18 Years65 YearsAll54Phase 4Germany
5EUCTR2010-023996-25-BE
(EUCTR)
21/12/201025/11/2010The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis. Multiple sclerosis (both relapsing remitting and progressive forms)Product Name: fluoxetine
Other descriptive name: FLUOXETINE
Product Name: Cisapride
INN or Proposed INN: CISAPRIDE
Product Name: Prucalopride
INN or Proposed INN: PRUCALOPRIDE
NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Belgium
6EUCTR2011-001692-39-DE
(EUCTR)
08/06/2011A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depressionA 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS patients with mild to moderate depression Multiple SclerosisDepression
MedDRA version: 14.1;Level: PT;Classification code 10012378;Term: Depression;System Organ Class: 10037175 - Psychiatric disorders
MedDRA version: 14.1;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Gilenya
Product Name: Gilenya
Other descriptive name: FINGOLIMOD HYDROCHLORIDE
Trade Name: Venlafaxin Hexal
Product Name: Venlafaxin Hexal
Other descriptive name: VENLAFAXINE HYDROCHLORIDE
Trade Name: Fluoxetin Hexal
Product Name: Fluoxetin Hexal
INN or Proposed INN: FLUOXETINE HYDROCHLORIDE
Trade Name: Venlafaxin Hexal
Product Name: Venlafaxin Hexal
Other descriptive name: VENLAFAXINE HYDROCHLORIDE
Trade Name: Fluoxetin Hexal
Product Name: Fluoxetin Hexal
INN or Proposed INN: FLUOXETINE HYDROCHLORIDE
Trade Name: Gilenya
Product Name: Gilenya
Other descriptive name: FINGOLIMOD HYDROCHLORIDE
Novartis Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
Germany

179. ウィリアムズ症候群


臨床試験数 : 5 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 32
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00768820
(ClinicalTrials.gov)
May 20017/10/2008The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeThe Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular FactorsVelocardiofacial Syndrome;Williams Syndrome;Fragile X SyndromeDrug: methylphenidate, fluoxetin, risperidoneThe Chaim Sheba Medical CenterNULLRecruitingN/AN/AAll400Phase 4Israel

206. 脆弱X症候群


臨床試験数 : 108 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00768820
(ClinicalTrials.gov)
May 20017/10/2008The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeThe Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular FactorsVelocardiofacial Syndrome;Williams Syndrome;Fragile X SyndromeDrug: methylphenidate, fluoxetin, risperidoneThe Chaim Sheba Medical CenterNULLRecruitingN/AN/AAll400Phase 4Israel